Clinical Development of Colony-Stimulating Factor 1 Receptor (CSF1R) Inhibitors

Area of Science:

• Immunology
• Oncology
• Pharmacology

Background:

• Macrophage infiltration is a poor prognostic indicator in many cancers.
• Macrophages play a key role in promoting tumor growth and progression.
• Targeting these innate immune cells presents a therapeutic opportunity.

Purpose of the Study:

• To review the efficacy and safety of CSF1 pathway inhibitors in cancer treatment.
• To explore combination strategies involving CSF1 inhibitors, particularly with immune checkpoint blockers.
• To provide an overview of agents in clinical development.

Main Methods:

• Review of clinical trial data and preclinical studies on CSF1 pathway inhibitors.
• Analysis of monoclonal antibodies targeting CSF1 or its receptor.
• Examination of tyrosine kinase inhibitors targeting the CSF1 receptor.
• Literature search for combination therapies, focusing on anti-PD-1/PD-L1 antibodies.

Main Results:

• CSF1 receptor blockade is a selective strategy to modulate tumor-associated macrophages.
• Various CSF1 receptor tyrosine kinase inhibitors, anti-CSF1 receptor antibodies, and anti-CSF1 antibodies are in clinical development.
• Combination therapies, especially with anti-PD-1/PD-L1, show potential for enhanced anti-tumor activity.

Conclusions:

• Targeting the CSF1 pathway offers a novel approach to cancer immunotherapy.
• Further clinical investigation of CSF1 pathway inhibitors and their combinations is warranted.
• Modulating the tumor microenvironment by targeting macrophages can improve cancer treatment outcomes.